Stockscreener 앱 받기
28.14
2.26%
-0.65
시장 영업 전:
27.60
-0.54
-1.92%
전일 마감가:
$28.79
열려 있는:
$28.69
하루 거래량:
874.38K
Relative Volume:
0.85
시가총액:
$1.67B
수익:
$66.05M
순이익/손실:
$-422.60M
주가수익비율:
-3.8808
EPS:
-7.251
순현금흐름:
$-384.73M
1주 성능:
-0.11%
1개월 성능:
+5.31%
6개월 성능:
+11.49%
1년 성능:
-4.90%
1일 변동 폭
$28.04
$29.10
1주일 범위
$27.45
$29.10
52주 변동 폭
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
명칭
Agios Pharmaceuticals Inc
전화
617-649-8600
주소
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
28.14 | 1.71B | 66.05M | -422.60M | -384.73M | -7.251 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-20 | 재확인 | H.C. Wainwright | Buy |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-20 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | 개시 | H.C. Wainwright | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-09-27 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-03 | 개시 | Piper Sandler | Overweight |
| 2022-11-17 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-27 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-10 | 개시 | H.C. Wainwright | Buy |
| 2021-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-03-01 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-02-15 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | 개시 | Leerink Partners | Mkt Perform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-04-11 | 재확인 | Credit Suisse | Outperform |
| 2018-02-15 | 재확인 | Needham | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-08-10 | 재확인 | Needham | Buy |
| 2017-08-08 | 재확인 | SunTrust | Buy |
| 2017-08-02 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-01-17 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2016-10-24 | 개시 | Needham | Buy |
| 2016-06-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2016-05-18 | 재확인 | SunTrust | Buy |
모두보기
Agios Pharmaceuticals Inc 주식(AGIO)의 최신 뉴스
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe - TradingView
Agios Pharmaceuticals Gains EU Approval for PYRUKYND in Adult Thalassaemia - World Business Outlook
Agios, Partner von Avanzanite Bioscience, gibt die Zulassung von PYRUKYND® (Mitapivat) in der Europäischen Union für Erwachsene mit Thalassämie bekannt - The Joplin Globe
Agios Pharmaceuticals (AGIO) Secures EU Approval for PYRUKYND - GuruFocus
EU approves mitapivat for thalassaemia treatment in adults - Investing.com UK
EU approves mitapivat for thalassaemia treatment in adults By Investing.com - Investing.com Nigeria
Avanzanite Bioscience's partner Agios announces Pyrukynd® (mitapivat) approval in EU - marketscreener.com
Agios Gets EU Approval for Pyrukynd in Thalassemia - Moomoo
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia - standard-journal.com
New oral thalassemia drug PYRUKYND approved for adults in EU - Stock Titan
Agios' Pyrukynd® (mitapivat) approved in the European Union for adults with thalassemia - marketscreener.com
Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia - The Manila Times
Agios Pharmaceuticals Receives EU Approval for PYRUKYND® as First Medicine for Thalassemia Treatment in Adults - Quiver Quantitative
(AGIO) Volatility Zones as Tactical Triggers - Stock Traders Daily
Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances - Yahoo Finance
Agios Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
AGIO beats on Q1 earnings & sales, stock up 13% on new drug momentum - MSN
Why is Agios Pharmaceuticals stock surging Tuesday afternoon? - MSN
Agios plans Q2 sNDA filing for mitapivat in sickle cell disease while citing >$10B 2030 market opportunity - MSN
How Investors Are Reacting To Agios Pharmaceuticals (AGIO) FDA Bid For Mitapivat In Sickle Cell Disease - Sahm
Armistice Capital (NASDAQ: AGIO) holds 2.716M shares, 4.57% stake - Stock Titan
Assessing Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Volatility - Yahoo Finance
How Agios’ Mitapivat sNDA And New SCD Trial Design At Agios Pharmaceuticals (AGIO) Has Changed Its Investment Story - Yahoo Finance
Developer seeking FDA’s accelerated approval for mitapivat for SCD - Sickle Cell Disease News
TradingKey - TradingKey
Agios sNDA And EHA Plenary Put Mitapivat At Center Of Valuation - Yahoo Finance
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease - The Globe and Mail
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $41 - Moomoo
Agios Pharmaceuticals (AGIO) Showcases Promising Mitapivat Data at EHA 2026 - GuruFocus
Agios submits application for mitapivat in sickle cell disease - Investing.com UK
Agios presents mitapivat data at European hematology congress By Investing.com - Investing.com Australia
Agios submits application for mitapivat in sickle cell disease By Investing.com - Investing.com Australia
Agios presents mitapivat data at European hematology congress - Investing.com
Agios Pharmaceuticals to Present RISE UP Phase 3 Trial Results of Mitapivat in Sickle Cell Disease at EHA 2026 Plenary Session - Quiver Quantitative
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease - The Manila Times
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias - The Manila Times
New pill for sickle cell moves to FDA review, aims to cut transfusions - Stock Titan
Oral drug lifts hemoglobin in sickle cell and thalassemia trial - Stock Titan
Price-Driven Insight from (AGIO) for Rule-Based Strategy - Stock Traders Daily
47,414 Shares in Agios Pharmaceuticals, Inc. $AGIO Acquired by State of New Jersey Common Pension Fund D - MarketBeat
Number of shareholders of Agios Pharmaceuticals, Inc. – TRADEGATE:8AP - TradingView
Lynx1 (AGIO) discloses 5.1% stake — 3.01M shares reported - Stock Titan
Need To Know: Analysts Are Much More Bullish On Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenues - 富途牛牛
Agios Pharmaceuticals Stock Rises 11.2% on Strong Q1 2026 Aqvesme Launch and Pipeline Progress - IndexBox
Agios Pharmaceuticals (AGIO) Is Up 11.2% After Rare Disease Launch And FDA Acceleration NewsHas The Bull Case Changed? - Sahm
Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026) - Yahoo Finance
Agios Pharmaceuticals Inc (AGIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):